Institute of Electronics and Telecommunications, Peter the Great St.Petersburg Polytechnic University, Saint-Petersburg, Russia.
Institute of Electronics and Telecommunications, Peter the Great St.Petersburg Polytechnic University, Saint-Petersburg, Russia.
Comput Biol Med. 2022 Feb;141:105172. doi: 10.1016/j.compbiomed.2021.105172. Epub 2021 Dec 28.
The efforts made to prevent the spread of COVID-19 face specific challenges in diagnosing COVID-19 patients and differentiating them from patients with pulmonary edema. Although systemically administered pulmonary vasodilators and acetazolamide are of great benefit for treating pulmonary edema, they should not be used to treat COVID-19 as they carry the risk of several adverse consequences, including worsening the matching of ventilation and perfusion, impaired carbon dioxide transport, systemic hypotension, and increased work of breathing. This study proposes a machine learning-based method (EDECOVID-net) that automatically differentiates the COVID-19 symptoms from pulmonary edema in lung CT scans using radiomic features. To the best of our knowledge, EDECOVID-net is the first method to differentiate COVID-19 from pulmonary edema and a helpful tool for diagnosing COVID-19 at early stages. The EDECOVID-net has been proposed as a new machine learning-based method with some advantages, such as having simple structure and few mathematical calculations. In total, 13 717 imaging patches, including 5759 COVID-19 and 7958 edema images, were extracted using a CT incision by a specialist radiologist. The EDECOVID-net can distinguish the patients with COVID-19 from those with pulmonary edema with an accuracy of 0.98. In addition, the accuracy of the EDECOVID-net algorithm is compared with other machine learning methods, such as VGG-16 (Acc = 0.94), VGG-19 (Acc = 0.96), Xception (Acc = 0.95), ResNet101 (Acc = 0.97), and DenseNet20l (Acc = 0.97).
为了防止 COVID-19 的传播,人们在诊断 COVID-19 患者并将其与肺水肿患者区分开来方面面临着特殊的挑战。虽然全身给予肺血管扩张剂和乙酰唑胺对治疗肺水肿有很大的益处,但不应将其用于治疗 COVID-19,因为它们有引起多种不良后果的风险,包括使通气和灌注匹配恶化、二氧化碳转运受损、全身低血压和呼吸功增加。本研究提出了一种基于机器学习的方法(EDECOVID-net),该方法使用放射组学特征自动从肺 CT 扫描中区分 COVID-19 症状和肺水肿。据我们所知,EDECOVID-net 是第一种将 COVID-19 与肺水肿区分开来的方法,也是早期诊断 COVID-19 的有用工具。EDECOVID-net 已被提出作为一种新的基于机器学习的方法,具有结构简单、数学计算少等优点。总共提取了 13717 个成像斑块,包括 5759 个 COVID-19 和 7958 个水肿图像,由专家放射科医生使用 CT 切口提取。EDECOVID-net 可以将 COVID-19 患者与肺水肿患者区分开来,准确率为 0.98。此外,还将 EDECOVID-net 算法的准确性与其他机器学习方法(如 VGG-16(Acc=0.94)、VGG-19(Acc=0.96)、Xception(Acc=0.95)、ResNet101(Acc=0.97)和 DenseNet201(Acc=0.97))进行了比较。